Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 11/20 | 0.48 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | PLK4 | O00444 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL56788 | 0.84 | MAPT (0.46) | IGF1RNTRK1PIK3C3GSK3B | |
| SCHEMBL2570120 | 0.83 | IGF1R (0.39) | IGF1RNTRK1PIK3C3GSK3BJAK2 | |
| SCHEMBL220024 | 0.83 | JAK2 (0.47) | IGF1RNTRK1PLK4PAK4JAK2 | |
| SCHEMBL3669544 | 0.82 | PIN1 (0.54) | PIN1IGF1RNTRK1PIK3C3GSK3B | |
| SCHEMBL2569472 | 0.81 | IGF1R (0.38) | IGF1RNTRK1PIK3C3GSK3BJAK2 | |
| SCHEMBL218889 | 0.81 | IGF1R (0.44) | IGF1RNTRK1PLK4PAK4JAK2 | |
| SCHEMBL4064988 | 0.81 | JAK2 (0.43) | IGF1RNTRK1PLK4PAK4JAK2 | |
| SCHEMBL27690873 | 0.79 | MEN1 (0.43) | IGF1RPIK3C3GSK3BJAK2JAK3 | |
| SCHEMBL4697054 | 0.78 | NTRK1 (0.54) | IGF1RNTRK1JAK2JAK3 | |
| SCHEMBL27698137 | 0.76 | IGF1R (0.39) | IGF1RPIK3C3GSK3BJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011545-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-20140155394-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2014-06-05 | — | — | US | disclosed |
| US-8486966-B2 | 9-(pyrazol-3-yl)-9H-purine-2-amine and 3-(pyrazol-3-yl) -3H-imidazo[4,5-B] pyridin-5-amine derivatives and their use for the treatment of cancer | ASTRAZENECA AB (SE) | 2013-07-16 | — | — | US | disclosed |
| CN-101119988-B | Chemical compound | ASTRAZENECA AB | 2013-03-06 | — | — | CN | disclosed |
| US-20120122892-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8129403-B2 | e.g. 2-[9-(5-Cyclopropyl-1H-pyrazol-3-yl)-6-methyl-9H-purin-2-ylamino]-2-(4-fluorophenyl)ethanol; tropomyosin-related kinases (Trk's) inhibitor; anticarcinoganic agent; solid tumors and leukemia | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB | 2010-12-23 | — | — | US | disclosed |
| CN-101679426-A | 9- (pyrazol-3-yl) -9H-purin-2-amine and 3- (pyrazol-3-yl) -3H-imidazo [4, 5-b ] pyridin-5-amine derivatives and their use to treat cancer | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| EP-2152705-A1 | 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B]PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008135785-A1 | 9- (PYRAZOL- 3 -YL) - 9H- PURINE-2 -AMINE AND 3- (PYRAZ0L-3-YL) -3H-IMIDAZ0 [4, 5-B] PYRIDIN-5-AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | WO | disclosed |
| US-20080176872-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| EP-1853588-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-06-18 | — | — | EP | disclosed |
| CN-101119988-A | Chemical compound | ASTRAZENECA AB (SE) | 2008-02-06 | — | — | CN | disclosed |
| EP-1853588-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087530-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176872-A1 | Chemical Compounds | TP53, XPOT, KRAS | PIN1 893/4885IGF1R 3024/4885NTRK1 4732/4885 |
| US-20120122892-A1 | CHEMICAL COMPOUNDS | TP53, XPOT, KRAS | PIN1 848/4885IGF1R 2806/4885NTRK1 4681/4885 |
| US-20150011545-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | PIN1 1521/4885IGF1R 4085/4885NTRK1 4667/4885 |
| US-20140155394-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | PIN1 1521/4885IGF1R 4085/4885NTRK1 4667/4885 |
| US-20100324040-A1 | 9-(PYRAZOL-3-YL)-9H-PURINE-2-AMINE AND 3-(PYRAZOL-3-YL) -3H-IMIDAZO[4,5-B] PYRIDIN-5- AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | THPO, MPL, MCL1 | PIN1 3173/4885IGF1R 3134/4885NTRK1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.